intelligence360

The Intelligent News Source

Tag: jSonar

Waltham Massachusetts based jSonar is raising $50,000,000.00 in New Equity Investment.

Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, jSonar is raising $50,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ron Ben-Natan played a key…

intelligence360

Source: http://go.intelligence360.io/ and https://intelligence360.news/

Howmet Aerospace Inc., which manufactures jet engine and industrial gas turbine components, is working to build a ceramic core production building on property it already owns in Whitehall. The $108 million facility would include 107,000 square feet of manufacturing space and 4,500 square feet of office space. the Michigan Strategic Fund board has approved a request for a $5.1 million Michigan Business Development Program Grant and a State Essential Services Assessment exemption, worth up to $1.6 million. The facility is expected to bring up to 300 new jobs to Muskegon County. Howmet, which launched operations in Whitehall in 1952 and has nine plants in the city and currently employs about 2,440 people in Whitehall. Howmet Aerospace is based in Pittsburgh, Pennsylvania, and has over 23,000 employees worldwide. Some of its leading customers include Pratt & Whitney, Airbus, Lockheed Martin and Boeing.

In a statement, Ben Squires, Howmet Aerospace director of government affairs said, “Our leadership had to consider multiple factors when making an investment decision of such a substantial scale.” Support of the Michigan Economic Development Corporation, the city of Whitehall and others helped seal the deal for the company’s expansion in West Michigan. The city of Whitehall is also expected to approve a property tax cut for the project.

Source: http://go.intelligence360.io/ and https://intelligence360.news/

A2 Biotherapeutics, has announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that includes The Column Group and Samsara BioCapital. Proceeds will fund the company’s three clinical development programs and advancement of its pipeline of CAR-T cell therapies based on its proprietary Tmod platform technology.

In a statement Jim Robinson, chief executive officer of A2 Bio said, “We are excited by the initial clinical data from our lead programs, which we believe validates our proprietary logic-gate technology approach to solid tumor cancers.” “This funding will enable us to continue ongoing clinical development of our CAR-T cell therapies as well as fund the potential next phase of development.”

A2 Biotherapeutics is a clinical-stage biotech company developing first-in-class logic-gated cell therapies to address the high unmet need in cancers. A2 Bio invented the proprietary Tmod™ cell therapy platform to tackle the fundamental challenge in cancer treatment—the ability of cancer medicines to distinguish between tumor and normal cells. A2 Biotherapeutics, established in 2018, is a fully integrated discovery, development and manufacturing company based in Agoura Hills, Calif. A2 Bio plans to direct the Series C funds to support the company’s three clinical studies, as well as to advance preclinical programs using its Tmod™ platform for potential clinical targets representing significant unmet needs in cancer and beyond.

Load More... Subscribe